University of Massachusetts

Sichuan University

Phillip Tai

Guangping Gao

Phillip D Zamore

Yi Lu

Qiang Zheng

Yuquan Wei

Xun Xu

Jianzhong Ai

Guangchao Xu

Li Luo

Wei Zhan

Manish Muhuri

Xu Xun

Elisabet C Mandon

In some aspects, the disclosure provides recombinant AAV and nucleic acid constructs having novel inverted terminal repeats (ITRs), cap, and/or rep genes. In some aspects, the disclosure relates to gene transfer methods using rAAVs described herein.

Use of inverted terminal repeats (ITRS) from adeno-associated virus serotypes 8 and RH.39 in gene therapy vectors

The disclosure relates, in some aspects, to compositions and methods for treating corneal disease (e.g., corneal neovascularization. In some embodiments, the disclosure relates to rAAV-mediated delivery of an cornea-associated transgene to a subject. In some embodiments, the rAAV transduces the corneal tissue of a subject.

Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization

The disclosure, in some aspects, relates to nucleic acids, compositions and kits useful for gene therapy with reduced immune response to transgene products.

Use of novel miRNA-binding site cassettes for antigen-presenting cell detargeting of transgene expression by rAAV gene therapy vectors

The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.

AAV capsid designs

Growing community of inventors

Worcester, MA, United States of America

Phillip Tai